19 April 2024 Scandion Oncology – Notice convening the Annual General Meeting Download Presentation Webcast Workbook
19 April 2024 SCANDION ONCOLOGY CARRIES OUT A RIGHTS ISSUE OF APPROXIMATELY SEK 60 MILLION SECURED UP TO APPROXIMATELY SEK 30.6 MILLION Download Presentation Webcast Workbook
21 March 2024 Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival Download Presentation Webcast Workbook
7 March 2024 Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial Download Presentation Webcast Workbook
22 February 2024 Invitation to Scandion Oncology webcast and conference call February 28, 2024 Download Presentation Webcast Workbook
31 January 2024 Scandion Oncology reports positive topline Phase IIa data from the CORIST Part 3 trial Download Presentation Webcast Workbook
5 January 2024 Scandion Oncology receives Notice of Allowance for patent to enhance US patent exclusivity on SCO-101 Download Presentation Webcast Workbook
21 December 2023 CORIST part 3 topline data are expected in the second half of January 2024 Download Presentation Webcast Workbook
15 December 2023 Scandion Oncology identifies potentially effective treatment of gastric cancer Download Presentation Webcast Workbook
29 November 2023 Scandion Oncology is granted new Composition of Matter-patent on lead compound SCO-101 extending its exclusivity until at least 2042 Download Presentation Webcast Workbook